Study Demonstrates AspenBio Pharma, Inc.’s AppyScore Multi-Marker Blood Test Highly Predictive for Absence of Acute Appendicitis in Children with Abdominal Pain

CASTLE ROCK, Colo.--(BUSINESS WIRE)--The final results from AspenBio Pharma’s (NASDAQ: APPY) 503-patient pilot study of AppyScore™ will be presented from the podium at the annual meeting of the Society for Academic Emergency Medicine being held in Chicago, May 9-12.